Physician profile
Thomas Mcandrew
NPI 1033314901
$5,031.12
in general payments reported to CMS, 2019-2025
35 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $1,210 · 2021: $731 · 2022: $245 · 2023: $363 · 2024: $471 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $926.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $684.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $569.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $455.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $343.69 | 2021-2025 | |
| Amarin Pharma, INC. | $248.52 | 2019-2021 | |
| Lilly USA, LLC | $230.18 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $190.83 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $167.15 | 2019-2023 | Livalo |
| Allergan, INC. | $154.29 | 2019-2020 | |
| Astellas Pharma US INC | $151.25 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $136.40 | 2019-2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $100.85 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $89.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.02 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.07 | 2019-2025 | Jardiance |
| Abbott Laboratories | $58.96 | 2022-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $50.94 | 2024-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $45.17 | 2025 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2019-2021 | |
| Boston Scientific Corporation | $27.42 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $24.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.88 | 2023 | |
| Medtronic USA, INC. | $17.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.20 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $14.83 | 2020 | |
| Optinose US, INC. | $14.72 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.22 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.14 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $13.02 | 2020 | |
| Bausch Health US, LLC | $12.98 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.97 | 2021 | |
| Eisai INC. | $12.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcandrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.